EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Diagnosis and follow-up of the first case of Gaucher disease under enzyme replacement therapy in Senegal

Mohamed Keita, Blaise F Faye, Alioune B Senghor, Alioune B Diallo, Elimane S Bousso, Sokhna A Touré, Moussa Seck, Saliou Diop

Ghana Medical Journal · 23.05.2026 · 60 (1) · 48-51

DOI: 10.4314/gmj.v60i1.7 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Ghana Medical Journal, online erschienen am 23.05.2026. Verfasst von Mohamed Keita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Haematology Department of National Blood Transfusion Centre, Dakar, Senegal. Hauptthemen laut MEDLINE: Gaucher Disease, Enzyme Replacement Therapy, Glucosylceramidase. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gaucher disease is a rare inherited disorder caused by a deficiency of the lysosomal enzyme β-glucocerebrosidase, leading to the accumulation of glucocerebroside within macrophages. This accumulation results in a wide spectrum of clinical manifestations, which may be life-threatening in severe cases. We report the first documented case in Senegal of a patient with Gaucher disease successfully treated with enzyme replacement therapy. The diagnosis was established based on characteristic bone marrow findings showing Gaucher cells, together with markedly reduced β-glucocerebrosidase activity and elevated chitotriosidase levels. The disease was diagnosed at the age of 11 years, and regular intravenous enzyme replacement therapy was initiated. Treatment was well tolerated and resulted in significant clinical improvement and a marked enhancement in the patient’s quality of life. However, genetic confirmation by GBA1 mutation analysis could not be performed due to limited access to molecular testing, which represents an important limitation of this report and prevented precise molecular classification of the disease. This case highlights the importance of early diagnosis and timely initiation of enzyme replacement therapy to prevent severe complications in Gaucher disease. Long-term follow-up studies remain necessary to further evaluate the efficacy and safety of enzyme replacement therapy in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gaucher DiseaseEnzyme Replacement TherapyGlucosylceramidaseHumansSenegalChildFemaleHexosaminidasesMaleQuality of LifeFollow-Up StudiesTreatment Outcome

Stichwörter der Autor:innen

Enzyme replacement therapyGaucher diseaseGlucocerebrosidase deficiencyImiglucerase (Cerezyme)Treatment outcomes

Substanzen

GlucosylceramidasechitotriosidaseHexosaminidasesimiglucerase

Autor:innen und Institutionen

  • Clinical Haematology Department of National Blood Transfusion Centre, Dakar, Senegal.

Zitieren

APA

Keita, M., Faye, B. F., Senghor, A. B., Diallo, A. B., Bousso, E. S., Touré, S. A., Seck, M., & Diop, S. (2026). Diagnosis and follow-up of the first case of Gaucher disease under enzyme replacement therapy in Senegal. Ghana Medical Journal, 60(1), 48-51. https://doi.org/10.4314/gmj.v60i1.7

Vancouver

Keita M, Faye BF, Senghor AB, Diallo AB, Bousso ES, Touré SA, et al. Diagnosis and follow-up of the first case of Gaucher disease under enzyme replacement therapy in Senegal. Ghana Medical Journal. 2026;60(1):48-51. doi:10.4314/gmj.v60i1.7

BibTeX
@article{Keita2026,
  author = {Keita, Mohamed and Faye, Blaise F and Senghor, Alioune B and Diallo, Alioune B and Bousso, Elimane S and Touré, Sokhna A and Seck, Moussa and Diop, Saliou},
  title = {Diagnosis and follow-up of the first case of Gaucher disease under enzyme replacement therapy in Senegal},
  journal = {Ghana Medical Journal},
  year = {2026},
  volume = {60},
  number = {1},
  pages = {48--51},
  doi = {10.4314/gmj.v60i1.7}
}
Kostenlos starten →